Fox Chase Cancer Center News

PHILADELPHIA (March 2, 2022)—Shannon Lynch, PhD, MPH, assistant professor in the Cancer Prevention and Control research program at Fox Chase Cancer Center, has received the American Cancer Society (ACS) and Flatiron Health’s 2021 Real-World Data Impact Award. 

PHILADELPHIA (March 1, 2022)—Fox Chase Cancer Center’s Suzanne M. Miller, PhD, a professor in the Cancer Prevention and Control research program, has received a two-year research grant from the Prevent Cancer Foundation to support a project designed to test whether text messaging can effectively reduce urban cervical cancer disparities.

PHILADELPHIA (February 25, 2022)—In a study published in the prestigious journal Clinical Cancer Research, Fox Chase Cancer Center researchers show that specific categories of TP53 gene mutations are more likely to associate with CDKN2A gene mutations or high tumor mutation burden in some cases of head and neck cancer.

PHILADELPHIA (February 24, 2022)—Extraskeletal myxoid chondrosarcoma is a rare soft-tissue cancer that can be misdiagnosed. Now researchers at Fox Chase Cancer Center have identified a fusion gene that can help pathologists positively identify these tumors.

PHILADELPHIA (February 24, 2022)—John Karanicolas, PhD, co-leader of the Molecular Therapeutics research program at Fox Chase Cancer Center, has been awarded a $200,000 grant as part of the University City Science Center’s QED Proof-of-Concept Program. The grant will fund research into developing antibodies that could be activated selectively in a tumor by a small molecule.

PHILADELPHIA (February 23, 2022)—On Wednesday, March 2, Fox Chase Cancer Center will host its second annual Cancer Epigenetics Institute Symposium, “From Genes to Chromatin to Therapeutics.” This year’s all-day event will take place at The Franklin Institute in Philadelphia and will include a virtual option for those who cannot attend in person.

PHILADELPHIA (February 17, 2022)—Jonathan Chernoff, MD, PhD, Cancer Center Director at Fox Chase Cancer Center, was recently awarded a $50,000 grant from the Pennsylvania Breast Cancer Coalition.

PHILADELPHIA (February 17, 2022)—Researchers at Fox Chase Cancer Center have discovered that the Hippo signaling effector YAP1 is a master regulator of Nodal signaling in human embryonic stem cells (hESCs) for a process essential to human development.